Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice

References

• Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. Jama 2013; 310:2435-42; PMID:24327038; http://dx.doi.org/10.1001/jama.2013.280490.
   PubMed Web of Science ®Google Scholar
• MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med 2014; 174:564-74; PMID:24535015; http://dx.doi.org/10.1001/jamainternmed.2013.14673.
   PubMed Web of Science ®Google Scholar
• Agura ED, Vila E, Petersen FB, Shields AF, Thomas ED. The use of ranitidine in bone marrow transplantation. A review of 223 cases. Transplantation 1988; 46:53-6; PMID:3293286; http://dx.doi.org/10.1097/00007890-198807000-00008.
   PubMed Web of Science ®Google Scholar
• List AF, Beaird DH, Kummet T. Ranitidine-induced granulocytopenia: recurrence with cimetidine administration. Ann Intern Med 1988; 108:566-7; PMID:3348565; http://dx.doi.org/10.7326/0003-4819-108-4-566.
   PubMed Web of Science ®Google Scholar
• Cricco GP, Mohamad NA, Sambuco LA, Genre F, Croci M, Gutierrez AS, Medina VA, Bergoc RM, Rivera ES, Martin GA. Histamine regulates pancreatic carcinoma cell growth through H3 and H4 receptors. Inflamm Res 2008; 57 Suppl 1:S23-4; PMID:18345506; http://dx.doi.org/10.1007/s00011-007-0611-5.
   PubMedGoogle Scholar
• Boer K, Helinger E, Helinger A, Pocza P, Pos Z, Demeter P, Baranyai Z, Dede K, Darvas Z, Falus A. Decreased expression of histamine H1 and H4 receptors suggests disturbance of local regulation in human colorectal tumours by histamine. Eur J Cell Biol 2008; 87:227-36; PMID:18258331; http://dx.doi.org/10.1016/j.ejcb.2007.12.003.
   PubMed Web of Science ®Google Scholar
• Francis H, DeMorrow S, Venter J, Onori P, White M, Gaudio E, Francis T, Greene JF, Jr, Tran S, Meininger CJ et al. Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma. Gut 2012; 61:753-64; PMID:21873469; http://dx.doi.org/10.1136/gutjnl-2011-300007.
   PubMed Web of Science ®Google Scholar
• Medina VA, Rivera ES. Histamine receptors and cancer pharmacology. Br J Pharmacol 2010; 161:755-67; PMID:20636392; http://dx.doi.org/10.1111/j.1476-5381.2010.00961.x.
   PubMed Web of Science ®Google Scholar
• Jutel M, Blaser K, Akdis CA. Histamine receptors in immune regulation and allergen-specific immunotherapy. Immunol Allergy Clin North Am 2006; 26:245-59, vii; PMID:16701143; http://dx.doi.org/10.1016/j.iac.2006.02.006.
   PubMed Web of Science ®Google Scholar
• Porretti JC, Mohamad NA, Martin GA, Cricco GP. Fibroblasts induce epithelial to mesenchymal transition in breast tumor cells which is prevented by fibroblasts treatment with histamine in high concentration. Int J Biochem Cell Biol 2014; 51:29-38; PMID:24685678; http://dx.doi.org/10.1016/j.biocel.2014.03.016.
   PubMed Web of Science ®Google Scholar
• Cricco GP, Davio CA, Martin G, Engel N, Fitzsimons CP, Bergoc RM, Rivera ES. Histamine as an autocrine growth factor in experimental mammary carcinomas. Agents Actions 1994; 43:17-20; PMID:7741034; http://dx.doi.org/10.1007/BF02005757.
   PubMedGoogle Scholar
• Medina V, Cricco G, Nunez M, Martin G, Mohamad N, Correa-Fiz F, Sanchez-Jimenez F, Bergoc R, Rivera ES. Histamine-mediated signaling processes in human malignant mammary cells. Cancer Biol Ther 2006; 5:1462-71; PMID:17012845; http://dx.doi.org/10.4161/cbt.5.11.3273.
   PubMed Web of Science ®Google Scholar
• Tonnesen H, Knigge U, Bulow S, Damm P, Fischerman K, Hesselfeldt P, Hjortrup A, Pedersen IK, Pedersen VM, Siemssen OJ et al. Effect of cimetidine on survival after gastric cancer. Lancet 1988; 2:990-2; PMID:2902494; http://dx.doi.org/10.1016/S0140-6736(88)90743-X.
   PubMed Web of Science ®Google Scholar
• Burtin C, Noirot C, Scheinmann P, Galoppin L, Sabolovic D, Bernard P. Clinical improvement in advanced cancer disease after treatment combining histamine and H2-antihistaminics (ranitidine or cimetidine). Eur J Cancer Clin Oncol 1988; 24:161-7; PMID:3356203; http://dx.doi.org/10.1016/0277-5379(88)90247-7.
   PubMedGoogle Scholar
• Bolton E, King J, Morris DL. H2-antagonists in the treatment of colon and breast cancer. Semin Cancer Biol 2000; 10:3-10; PMID:10888265; http://dx.doi.org/10.1006/scbi.2000.0301.
   PubMed Web of Science ®Google Scholar
• Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, Diaz LA, Jr., Papadopoulos N, Kinzler KW, Vogelstein B et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A 2014; 111:11774-9; PMID:25071169; http://dx.doi.org/10.1073/pnas.1410626111.
   PubMed Web of Science ®Google Scholar
• Sinha P, Clements VK, Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 2005; 174:636-45; http://dx.doi.org/10.4049/jimmunol.174.2.636.
   PubMed Web of Science ®Google Scholar
• Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-β 1. J Immunol 2009; 182:240-9; PMID:19109155; http://dx.doi.org/10.4049/jimmunol.182.1.240.
   PubMed Web of Science ®Google Scholar
• Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, Lehner F, Manns MP, Greten TF, Korangy F. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 2009; 50:799-807; PMID:19551844; http://dx.doi.org/10.1002/hep.23054.
   PubMed Web of Science ®Google Scholar
• Poschke I, Mao Y, Adamson L, Salazar-Onfray F, Masucci G, Kiessling R. Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines. Cancer Immunol Immunother 2012; 61:827-38; PMID:22080405; http://dx.doi.org/10.1007/s00262-011-1143-y.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Deguchi K, Zheng R, Tamai H, Wang LX, Cohen PA, Shu S. Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol 2008; 181:3291-300; PMID:18714001; http://dx.doi.org/10.4049/jimmunol.181.5.3291.
   PubMed Web of Science ®Google Scholar
• Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111:4233-44; PMID:18272812; http://dx.doi.org/10.1182/blood-2007-07-099226.
   PubMed Web of Science ®Google Scholar
• Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66:1123-31; PMID:16424049; http://dx.doi.org/10.1158/0008-5472.CAN-05-1299.
   PubMed Web of Science ®Google Scholar
• Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11:6713-21; PMID:16166452; http://dx.doi.org/10.1158/1078-0432.CCR-05-0883.
   PubMed Web of Science ®Google Scholar
• Tongu M, Harashima N, Monma H, Inao T, Yamada T, Kawauchi H, Harada M. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol Immunother 2013; 62:383-91; PMID:22926062; http://dx.doi.org/10.1007/s00262-012-1343-0.
   PubMed Web of Science ®Google Scholar
• Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rebe C, Ghiringhelli F. Five-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010; 70:3052-61; PMID:20388795; http://dx.doi.org/10.1158/0008-5472.CAN-09-3690.
   PubMed Web of Science ®Google Scholar
• Wesolowski R, Markowitz J, Carson WE, 3rd. Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer 2013; 1:10; PMID:24829747; http://dx.doi.org/10.1186/2051-1426-1-10.
   PubMedGoogle Scholar
• Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182:4499-506; PMID:19342621; http://dx.doi.org/10.4049/jimmunol.0802740.
   PubMed Web of Science ®Google Scholar
• Mazzoni A, Young HA, Spitzer JH, Visintin A, Segal DM. Histamine regulates cytokine production in maturing dendritic cells, resulting in altered T cell polarization. J Clin Invest 2001; 108:1865-73; PMID:11748270; http://dx.doi.org/10.1172/JCI200113930.
   PubMed Web of Science ®Google Scholar
• van der Pouw Kraan TC, Snijders A, Boeije LC, de Groot ER, Alewijnse AE, Leurs R, Aarden LA. Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. J Clin Invest 1998; 102:1866-73; PMID:9819373; http://dx.doi.org/10.1172/JCI3692.
   PubMed Web of Science ®Google Scholar
• Zhang J, Takahashi HK, Liu K, Wake H, Liu R, Sadamori H, Matsuda H, Yagi T, Yoshino T, Mori S et al. Histamine inhibits adhesion molecule expression in human monocytes, induced by advanced glycation end products, during the mixed lymphocyte reaction. Br J Pharmacol 2010; 160:1378-86; PMID:20590628; http://dx.doi.org/10.1111/j.1476-5381.2010.00800.x.
   PubMed Web of Science ®Google Scholar
• Dawicki W, Jawdat DW, Xu N, Marshall JS. Mast cells, histamine, and IL-6 regulate the selective influx of dendritic cell subsets into an inflamed lymph node. J Immunol 2010; 184:2116-23; PMID:20083654; http://dx.doi.org/10.4049/jimmunol.0803894.
   PubMed Web of Science ®Google Scholar
• Asea A, Hermodsson S, Hellstrand K. Histaminergic regulation of natural killer cell-mediated clearance of tumour cells in mice. Scand J Immunol 1996; 43:9-15; PMID:8560202; http://dx.doi.org/10.1046/j.1365-3083.1996.d01-14.x.
   PubMed Web of Science ®Google Scholar
• Hellstrand K, Asea A, Hermodsson S. Role of histamine in natural killer cell-mediated resistance against tumor cells. J Immunol 1990; 145:4365-70; PMID:2147942
   PubMed Web of Science ®Google Scholar
• Jutel M, Watanabe T, Klunker S, Akdis M, Thomet OA, Malolepszy J, Zak-Nejmark T, Koga R, Kobayashi T, Blaser K et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 2001; 413:420-5; PMID:11574888; http://dx.doi.org/10.1038/35096564.
   PubMed Web of Science ®Google Scholar
• Osna N, Elliott K, Khan MM. Regulation of interleukin-10 secretion by histamine in TH2 cells and splenocytes. Int Immunopharmacol 2001; 1:85-96; PMID:11367520; http://dx.doi.org/10.1016/S0162-3109(00)00268-X.
   PubMed Web of Science ®Google Scholar
• Osna N, Elliott K, Khan MM. The effects of histamine on interferon gamma production are dependent on the stimulatory signals. Int Immunopharmacol 2001; 1:135-45; PMID:11367511; http://dx.doi.org/10.1016/S1567-5769(00)00005-9.
   PubMed Web of Science ®Google Scholar
• Khan MM, Keaney KM, Melmon KL, Clayberger C, Krensky AM. Histamine regulates the generation of human cytolytic T lymphocytes. Cell Immunol 1989; 121:60-73; PMID:2541932; http://dx.doi.org/10.1016/0008-8749(89)90005-1.
   PubMed Web of Science ®Google Scholar
• Yang XD, Ai W, Asfaha S, Bhagat G, Friedman RA, Jin G, Park H, Shykind B, Diacovo TG, Falus A et al. Histamine deficiency promotes inflammation-associated carcinogenesis through reduced myeloid maturation and accumulation of CD11b+Ly6G+ immature myeloid cells. Nat Med 2011; 17:87-95; PMID:21170045; http://dx.doi.org/10.1038/nm.2278.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Xu M, Li X, Jia J, Fan K, Lai G. Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells. Mol Immunol 2013; 54:74-83; PMID:23220070; http://dx.doi.org/10.1016/j.molimm.2012.10.035.
   PubMed Web of Science ®Google Scholar
• Martin RK, Saleem SJ, Folgosa L, Zellner HB, Damle SR, Nguyen GK, Ryan JJ, Bear HD, Irani AM, Conrad DH. Mast cell histamine promotes the immunoregulatory activity of myeloid-derived suppressor cells. J Leukoc Biol 2014; 96:151-9; PMID:24610880; http://dx.doi.org/10.1189/jlb.5A1213-644R.
   PubMed Web of Science ®Google Scholar
• Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 2009; 9:900-9; PMID:19336265; http://dx.doi.org/10.1016/j.intimp.2009.03.015.
   PubMed Web of Science ®Google Scholar
• Lemos B, Davio C, Gass H, Gonzalez P, Cricco G, Martin G, Bergoc R, Rivera E. Histamine receptors in human mammary gland, different benign lesions and mammary carcinomas. Inflamm Res 1995; 44 Suppl 1:S68-9; PMID:8521007; http://dx.doi.org/10.1007/BF01674400.
   Google Scholar
• Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A, Segal DM, Staib C, Lowel M, Sutter G et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol 2003; 170:270-8; PMID:12496409; http://dx.doi.org/10.4049/jimmunol.170.1.270.
   PubMed Web of Science ®Google Scholar
• Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007; 67:4507-13; PMID:17483367; http://dx.doi.org/10.1158/0008-5472.CAN-06-4174.
   PubMed Web of Science ®Google Scholar
• Gujar SA, Clements D, Dielschneider R, Helson E, Marcato P, Lee PW. Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms. Br J Cancer 2014; 110:83-93; PMID:24281006; http://dx.doi.org/10.1038/bjc.2013.695.
   PubMed Web of Science ®Google Scholar
• Andrade-Vieira R, Xu Z, Colp P, Marignani PA. Loss of LKB1 expression reduces the latency of ErbB2-mediated mammary gland tumorigenesis, promoting changes in metabolic pathways. PloS One 2013; 8:e56567; PMID:23451056; http://dx.doi.org/10.1371/journal.pone.00-56567.
   PubMedGoogle Scholar
• Hellstrand K, Asea A, Dahlgren C, Hermodsson S. Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites. J Immunol 1994; 153:4940-7; PMID:7963557
   PubMed Web of Science ®Google Scholar
• Hansson M, Hermodsson S, Brune M, Mellqvist UH, Naredi P, Betten A, Gehlsen KR, Hellstrand K. Histamine protects T cells and natural killer cells against oxidative stress. J Interferon Cytokine Res 1999; 19:1135-44; PMID:10547153; http://dx.doi.org/10.1089/107999099313073.
   PubMed Web of Science ®Google Scholar
• Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, Gonzalez R, Hersh E, Feun L, Belt R et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002; 20:125-33; PMID:11773161; http://dx.doi.org/10.1200/JCO.20.1.125.
   PubMed Web of Science ®Google Scholar
• Bowrey PF, King J, Magarey C, Schwartz P, Marr P, Bolton E, Morris DL. Histamine, mast cells and tumour cell proliferation in breast cancer: does preoperative cimetidine administration have an effect? Br J Cancer 2000; 82:167-70; PMID:10638985; http://dx.doi.org/10.1054/bjoc.1999.0895.
   PubMed Web of Science ®Google Scholar
• Hsu CL, Chang CH, Lin JW, Wu LC, Chuang LM, Lai MS. Histamine-2 receptor antagonists and risk of lung cancer in diabetic patients - an exploratory analysis. Pharmacoepidemiol Drug Saf 2013; 22:632-40; PMID:23576472; http://dx.doi.org/10.1002/pds.3441.
   PubMed Web of Science ®Google Scholar
• Seto CT, Jeraldo P, Orenstein R, Chia N, DiBaise JK. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome 2014; 2:42; PMID:25426290; http://dx.doi.org/10.1186/2049-2618-2-42.
   PubMed Web of Science ®Google Scholar
• Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffer PJ et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013; 504:451-5; PMID:24226773; http://dx.doi.org/10.1038/nature12726.
   PubMed Web of Science ®Google Scholar
• Wu HJ, Ivanov, II, Darce J, Hattori K, Shima T, Umesaki Y, Littman DR, Benoist C, Mathis D. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010; 32:815-27; PMID:20620945; http://dx.doi.org/10.1016/j.immuni.2010.06.001.
   PubMed Web of Science ®Google Scholar
• Lakritz JR, Poutahidis T, Mirabal S, Varian BJ, Levkovich T, Ibrahim YM, Ward JM, Teng EC, Fisher B, Parry N et al. Gut bacteria require neutrophils to promote mammary tumorigenesis. Oncotarget 2015; 6:9387-96; PMID:25831236; http://dx.doi.org/10.18632/oncotarget.3328.
   PubMed Web of Science ®Google Scholar
• Goh W, Sleptsova-Freidrich I, Petrovic N. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci 2014; 17:439-46; PMID:25224353.
   PubMed Web of Science ®Google Scholar
• Jin UH, Lee SO, Pfent C, Safe S. The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis. BMC Cancer 2014; 14:498; PMID:25011475; http://dx.doi.org/10.1186/1471-2407-14-498.
   PubMed Web of Science ®Google Scholar
• Panni RZ, Linehan DC, DeNardo DG. Targeting tumor-infiltrating macrophages to combat cancer. Immunotherapy 2013; 5:1075-87; PMID:24088077; http://dx.doi.org/10.2217/imt.13.102.
   PubMed Web of Science ®Google Scholar
• Ward R, Sims AH, Lee A, Lo C, Wynne L, Yusuf H, Gregson H, Lisanti MP, Sotgia F, Landberg G et al. Monocytes and macrophages, implications for breast cancer migration and stem cell-like activity and treatment. Oncotarget 2015; 6:14687-99.
   PubMed Web of Science ®Google Scholar
• Sharma SK, Chintala NK, Vadrevu SK, Patel J, Karbowniczek M, Markiewski MM. Pulmonary alveolar macrophages contribute to the premetastatic niche by suppressing antitumor T cell responses in the lungs. J Immunol 2015; 194:5529-38; http://dx.doi.org/10.4049/jimmunol.1403215; PMID:26008983; http://dx.doi.org/10.18632/oncotarget.4189
   PubMed Web of Science ®Google Scholar
• Haile LA, Gamrekelashvili J, Manns MP, Korangy F, Greten TF. CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice. J Immunol 2010; 185:203-10; PMID:20525890; http://dx.doi.org/10.4049/jimmunol.0903573.
   PubMed Web of Science ®Google Scholar
• Oh K, Lee OY, Shon SY, Nam O, Ryu PM, Seo MW, Lee DS. A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. Breast Cancer Res 2013; 15:R79; PMID:24021059; http://dx.doi.org/10.1186/bcr3473.
   PubMed Web of Science ®Google Scholar
• OuYang LY, Wu XJ, Ye SB, Zhang RX, Li ZL, Liao W, Pan ZZ, Zheng LM, Zhang XS, Wang Z et al. Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer. J Transl Med 2015; 13:47; PMID:25638150; http://dx.doi.org/10.1186/s12967-015-0410-7.
   PubMed Web of Science ®Google Scholar
• Bergenfelz C, Larsson AM, von Stedingk K, Gruvberger-Saal S, Aaltonen K, Jansson S, Jernstrom H, Janols H, Wullt M, Bredberg A et al. Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients. PloS One 2015; 10:e0127028; PMID:25992611; http://dx.doi.org/10.1371/journal.pone.0127028.
   PubMed Web of Science ®Google Scholar
• Saleem SJ, Martin RK, Morales JK, Sturgill JL, Gibb DR, Graham L, Bear HD, Manjili MH, Ryan JJ, Conrad DH. Cutting edge: mast cells critically augment myeloid-derived suppressor cell activity. J Immunol 2012; 189:511-5; PMID:22706087; http://dx.doi.org/10.4049/jimmunol.1200647.
   PubMed Web of Science ®Google Scholar
• Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 2009; 182:5693-701; PMID:19380816; http://dx.doi.org/10.4049/jimmunol.0900092.
   PubMed Web of Science ®Google Scholar
• Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res 2001; 61:4756-60; PMID:11406548.
   PubMed Web of Science ®Google Scholar
• Zhu J, Huang X, Yang Y. Myeloid-derived suppressor cells regulate natural killer cell response to adenovirus-mediated gene transfer. J Virol 2012; 86:13689-96; PMID:23055553; http://dx.doi.org/10.1128/JVI.01595-12.
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL, Schneck J, Gabrilovich DI. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13:828-35; PMID:17603493; http://dx.doi.org/10.1038/nm1609.
   PubMed Web of Science ®Google Scholar
• Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD, Chen W, Wahl SM, Ledbetter S, Pratt B et al. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003; 198:1741-52; PMID:14657224; http://dx.doi.org/10.1084/jem.20022227.
   PubMed Web of Science ®Google Scholar
• Fichtner-Feigl S, Terabe M, Kitani A, Young CA, Fuss I, Geissler EK, Schlitt HJ, Berzofsky JA, Strober W. Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-α 2. Cancer Res 2008; 68:3467-75; PMID:18451175; http://dx.doi.org/10.1158/0008-5472.CAN-07-5301.
   PubMed Web of Science ®Google Scholar
• Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007; 25:2546-53; PMID:17577033; http://dx.doi.org/10.1200/JCO.2006.08.5829.
   PubMed Web of Science ®Google Scholar
• Weizman N, Krelin Y, Shabtay-Orbach A, Amit M, Binenbaum Y, Wong RJ, Gil Z. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase. Oncogene 2014; 33:3812-9; PMID:23995783; http://dx.doi.org/10.1038/onc.2013.357.
   PubMed Web of Science ®Google Scholar
• Perez-Diez A, Joncker NT, Choi K, Chan WF, Anderson CC, Lantz O, Matzinger P. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007; 109:5346-54; PMID:17327412; http://dx.doi.org/10.1182/blood-2006-10-051318.
   PubMed Web of Science ®Google Scholar
• Tsukamoto H, Nishikata R, Senju S, Nishimura Y. Myeloid-derived suppressor cells attenuate TH1 development through IL-6 production to promote tumor progression. Cancer Immunol Res 2013; 1:64-76; PMID:24777249; http://dx.doi.org/10.1158/2326-6066.CIR-13-0030.
   PubMed Web of Science ®Google Scholar
• Crook KR, Jin M, Weeks MF, Rampersad RR, Baldi RM, Glekas AS, Shen Y, Esserman DA, Little P, Schwartz TA et al. Myeloid-derived suppressor cells regulate T cell and B cell responses during autoimmune disease. J Leukoc Biol 2015; 97:573-82; PMID:25583578; http://dx.doi.org/10.1189/jlb.4A0314-139R.
   PubMed Web of Science ®Google Scholar
• Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, Greten TF, Korangy F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008; 135:234-43; PMID:18485901; http://dx.doi.org/10.1053/j.gastro.2008.03.020.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Numata K, Ito T, Takagi K, Matsukawa A. Innate immune response in Th1- and Th2-dominant mouse strains. Shock 2004; 22:460-6; PMID:15489639; http://dx.doi.org/10.1097/01.shk.0000142249.08135.e9.
   PubMed Web of Science ®Google Scholar
• Chen X, Oppenheim JJ, Howard OM. BALB/c mice have more CD4+CD25+ T regulatory cells and show greater susceptibility to suppression of their CD4+CD25- responder T cells than C57BL/6 mice. J Leukoc Biol 2005; 78:114-21; PMID:15845645; http://dx.doi.org/10.1189/jlb.0604341.
   PubMed Web of Science ®Google Scholar
• Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 1998; 58:1486-93; PMID:9537252.
   PubMed Web of Science ®Google Scholar
• Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011; 475:222-5; PMID:21654748; http://dx.doi.org/10.1038/nature10138.
   PubMed Web of Science ®Google Scholar
• Vehabovic M, Hadzovic S, Stambolic F, Hadzic A, Vranjes E, Haracic E. Stability of ranitidine in injectable solutions. Int J Pharm 2003; 256:109-15; PMID:12695016; http://dx.doi.org/10.1016/S0378-5173(03)00067-X.
   PubMed Web of Science ®Google Scholar
• Bullock LS, Fitzgerald JF, Mazur HI. Stability of intravenous famotidine stored in polyvinyl chloride syringes. DICP 1989; 23:588-90; PMID:2763581.
   PubMedGoogle Scholar
• Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol 2001; Chapter 20:Unit 20 2; PMID:18432775; http://dx.doi.org/10.1002/0471142735.im2002s39
   PubMedGoogle Scholar